FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
Lee Pai-Scherf, Gideon M Blumenthal, Hongshan Li, Sriram Subramaniam, Pallavi S Mishra-Kalyani, Kun He, Hong Zhao, Jingyu Yu, Mark Paciga, Kirsten B Goldberg, Amy E McKee, Patricia Keegan, Richard Pazdur, Lee Pai-Scherf, Gideon M Blumenthal, Hongshan Li, Sriram Subramaniam, Pallavi S Mishra-Kalyani, Kun He, Hong Zhao, Jingyu Yu, Mark Paciga, Kirsten B Goldberg, Amy E McKee, Patricia Keegan, Richard Pazdur
Abstract
On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1) as determined by an FDA-approved test, as follows: (a) first-line treatment of patients with mNSCLC whose tumors have high PD-L1 expression (tumor proportion score [TPS] ≥50%), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and (b) treatment of patients with mNSCLC whose tumors express PD-L1 (TPS ≥1%), with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving pembrolizumab.Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) for patients randomized to pembrolizumab compared with chemotherapy. In KEYNOTE-024, patients with previously untreated mNSCLC who received pembrolizumab (200 mg intravenously [IV] every 3 weeks) had a statistically significant improvement in OS (hazard ratio [HR] 0.60; 95% confidence interval [CI]: 0.41-0.89; p = .005), and significant improvement in PFS (HR 0.50; 95% CI: 0.37-0.68; p < .001). In KEYNOTE-010, patients with disease progression on or after platinum-containing chemotherapy received pembrolizumab IV 2 mg/kg, 10 mg/kg, or docetaxel 75 mg/m2 every 3 weeks. The HR and p value for OS was 0.71 (95% CI: 0.58-0.88), p < .001 comparing pembrolizumab 2 mg/kg with chemotherapy and the HR and p value for OS was 0.61 (95% CI: 0.49-0.75), p < .001 comparing pembrolizumab 10 mg/kg with chemotherapy.
Implications for practice: This is the first U.S. Food and Drug Administration approval of a checkpoint inhibitor for first-line treatment of lung cancer. This approval expands the pembrolizumab indication in second-line treatment of lung cancer to include all patients with programmed death-ligand 1-expressing non-small cell lung cancer.
Keywords: EGFR protein, Human; Non‐small cell lung cancer; Pembrolizumab; United States Food and Drug Administration.
Conflict of interest statement
Disclosures of potential conflicts of interest may be found at the end of this article.
Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Figures
References
- D'Addario G, Pintilie M, Leighl NB et al. Platinum‐based versus non‐platinum based chemotherapy in advanced non‐small‐cell lung cancer: A meta‐analysis of the published literature. J Clin Oncol 2005;23:2926–2936.
- Taxotere Prescribing Information . Available at . Accessed July 19, 2017.
- Erlotinib Prescribing Information . Available at . Accessed July 19, 2017.
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology : Non‐small cell lung cancer. Available at . Accessed December 12, 2016.
- National Cancer Institute : Lung Cancer. Available at . Accessed December 12, 2016.
- Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non‐small cell lung cancer. N Engl J Med 2002;346:92–98.
- Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum‐based doublets in advanced non‐small cell lung cancer. J Clin Oncol 2002;20:4285–4291.
- Sul J, Blumenthal GM, Jiang X et al. FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non‐small cell lung cancer whose tumors express programmed death‐ligand 1. The Oncologist 2016;21:643–650.
- Reck M, Rodríguez‐Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD‐L1‐positive non‐small‐cell lung cancer. N Engl J Med 2016;375:1823–1833.
- Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD‐L1‐positive, advanced non‐small‐cell lung cancer (KEYNOTE‐010): A randomised controlled trial. Lancet 2016;387:1540–1550.
- Keytruda Prescribing Information . Available at . Accessed July 19, 2017.
- , Trial NCT02142738. Available at . Accessed July 19, 2017.
- , Trial NCT02220894. Available at . Accessed July 19, 2017.
Source: PubMed